Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AUA: Cryoablation Appears to Be Important Alternative Treatment for Prostate Cancer IRVINE, CA -- March 14, 2005 -- Endocare, Inc. (OTC: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation along with vacuum technologies for erectile dysfunction, today announced that 10-year follow-up data from a retrospective study demonstrated that cryoablation as a treatment for prostate cancer has a biochemical disease free survival rate of 77 percent. The data from the 10-year study was presented at the 69th Annual Meeting of the South East Section of the American Urological Association (AUA) in Charleston, SC on March 3, 2005. A patient was considered to be biochemically disease free if their PSA (Prostate-Specific Antigen) did not rise above 2.0 ng/ml at any point after therapy. This study also found that only 4 of the 230 patients treated died of prostate cancer indicating a prostate cancer specific survival of more than 98 percent. Fletcher C. Derrick, Jr., M.D., affiliated with Roper Hospital in Charleston, SC, was the principal investigator and author of the study. "It takes a long time to establish the effectiveness of a cancer therapy," Dr. Derrick said. "These 10-year results solidify the role of cryoablation as a safe, effective and durable procedure. This survival data on cryoablation, combined with its minimally invasive nature and its low morbidity rates, indicate its growing importance as a prostate cancer therapy." The 249-patient study is the longest outcomes study of cryoablation to date. Consistent with previously published and presented results from independent researchers and physicians, cryoablation appears to be an important alternative treatment for prostate cancer versus the current treatments including radical prostatectomy or radiation therapy. The study also found morbidity to be low. Only 2 percent of patients had severe incontinence and urethral rectal fistula occurred in less than 0.5 percent of patients. Erectile function returned with time and 50 percent of patients had some return of normal functioning beginning six months after therapy. Endocare Chairman and CEO Craig T. Davenport commented, "The publication of these latest clinical data, which have been collected over the past 10 years, continue to validate and confirm cryosurgery as a viable, and many times preferable, treatment option for prostate cancer. These data combined with abstracts, training classes and a plenary session at the national AUA meeting in San Antonio in May will provide urologists and healthcare payers with more data confirming the effectiveness of cryoablation and the positive improvements in morbidity compared to early trials and studies of the therapy." SOURCE: Endocare, Inc. E-mail this page to a friend or colleague! To print, use this version